$FEMY
FEMASYS INC

2023 Q3 Form 10-Q Financial Statement

#000114036123038918 Filed on August 10, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $244.4K $320.5K
YoY Change -29.67% 5.74%
Cost Of Revenue $86.19K $110.5K
YoY Change -34.43% 7.93%
Gross Profit $158.2K $210.0K
YoY Change -26.77% 4.62%
Gross Profit Margin 64.73% 65.53%
Selling, General & Admin $2.041M $1.486M
YoY Change 37.42% 19.31%
% of Gross Profit 1290.53% 707.25%
Research & Development $2.073M $1.527M
YoY Change 25.77% 3.68%
% of Gross Profit 1310.47% 727.07%
Depreciation & Amortization $131.7K $133.3K
YoY Change -5.67% -6.57%
% of Gross Profit 83.26% 63.47%
Operating Expenses $4.239M $3.146M
YoY Change 29.52% 9.97%
Operating Profit -$4.081M -$2.936M
YoY Change 33.5% 10.38%
Interest Expense $8.033K $198.00
YoY Change 33.77% -77.58%
% of Operating Profit
Other Income/Expense, Net $84.36K $42.45K
YoY Change 13.47% 64.16%
Pretax Income -$3.997M -$2.894M
YoY Change 34.0% 9.85%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$3.997M -$2.894M
YoY Change 34.0% 9.85%
Net Earnings / Revenue -1635.66% -902.77%
Basic Earnings Per Share -$0.26 -$0.22
Diluted Earnings Per Share -$0.26 -$0.22
COMMON SHARES
Basic Shares Outstanding 15.07M 13.19M
Diluted Shares Outstanding 15.09M 13.11M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $8.692M $10.71M
YoY Change -45.69% -44.0%
Cash & Equivalents $8.692M $10.71M
Short-Term Investments
Other Short-Term Assets $826.4K $587.8K
YoY Change 8.65% -31.25%
Inventory $602.7K $581.5K
Prepaid Expenses
Receivables $103.6K $155.7K
Other Receivables $0.00 $0.00
Total Short-Term Assets $10.23M $12.03M
YoY Change -40.87% -40.82%
LONG-TERM ASSETS
Property, Plant & Equipment $1.161M $1.255M
YoY Change -24.75% -23.02%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $937.0K $865.6K
YoY Change 18.66% 30.54%
Total Long-Term Assets $4.629M $2.284M
YoY Change 68.95% -18.18%
TOTAL ASSETS
Total Short-Term Assets $10.23M $12.03M
Total Long-Term Assets $4.629M $2.284M
Total Assets $14.85M $14.31M
YoY Change -25.85% -38.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $851.9K $546.9K
YoY Change 103.26% 27.68%
Accrued Expenses $569.4K $536.8K
YoY Change -12.34% -2.72%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $693.6K $209.1K
YoY Change 4.02% -74.26%
Total Short-Term Liabilities $2.187M $1.382M
YoY Change 20.98% -25.91%
LONG-TERM LIABILITIES
Long-Term Debt $2.169M $0.00
YoY Change 1773.52% -100.0%
Other Long-Term Liabilities $54.02K $56.25K
YoY Change -46.94% -48.46%
Total Long-Term Liabilities $2.223M $56.25K
YoY Change 921.7% -82.33%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.187M $1.382M
Total Long-Term Liabilities $2.223M $56.25K
Total Liabilities $4.410M $1.438M
YoY Change 117.74% -34.14%
SHAREHOLDERS EQUITY
Retained Earnings -$104.0M -$99.97M
YoY Change 13.95% 13.28%
Common Stock $16.11K $15.19K
YoY Change 35.03% 27.32%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $10.44M $12.88M
YoY Change
Total Liabilities & Shareholders Equity $14.85M $14.31M
YoY Change -25.85% -38.09%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$3.997M -$2.894M
YoY Change 34.0% 9.85%
Depreciation, Depletion And Amortization $131.7K $133.3K
YoY Change -5.67% -6.57%
Cash From Operating Activities -$2.855M -$2.741M
YoY Change 4.56% 15.18%
INVESTING ACTIVITIES
Capital Expenditures $29.02K $62.95K
YoY Change -256.53% -136.04%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$29.02K -$62.95K
YoY Change 56.53% -63.96%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 874.1K 3.348M
YoY Change -341.43% -3563.85%
NET CHANGE
Cash From Operating Activities -2.855M -2.741M
Cash From Investing Activities -29.02K -62.95K
Cash From Financing Activities 874.1K 3.348M
Net Change In Cash -2.010M 543.7K
YoY Change -35.4% -120.51%
FREE CASH FLOW
Cash From Operating Activities -$2.855M -$2.741M
Capital Expenditures $29.02K $62.95K
Free Cash Flow -$2.884M -$2.804M
YoY Change 6.34% 27.16%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
30024
dei City Area Code
CityAreaCode
770
dei Local Phone Number
LocalPhoneNumber
500-3910
dei Security12b Title
Security12bTitle
Common stock, $0.001 par value
dei Trading Symbol
TradingSymbol
FEMY
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001339005
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
42454
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
25862
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
137871
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
25582
CY2023Q2 femy Stock Issued During Period Value Issuance Of Common Stock And Warrants
StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrants
3345996
CY2023Q2 femy Stock Issued During Period Value At The Market Offering Net Of Issuance Costs
StockIssuedDuringPeriodValueAtTheMarketOfferingNetOfIssuanceCosts
0
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1697
CY2023Q2 femy Stock Issued During Period Value Exercise Of Pre Funded Warrants
StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants
188
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-2893508
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
122170
CY2022Q2 femy Expiration Of Warrant
ExpirationOfWarrant
0
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
16151
femy Deferred Offering Costs Included In Accounts Payable And Accrued Expenses
DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
0
femy Deferred Offering Costs Included In Accounts Payable And Accrued Expenses
DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
82760
femy Prepaid Insurance Financed With Promissory Note
PrepaidInsuranceFinancedWithPromissoryNote
0
femy Prepaid Insurance Financed With Promissory Note
PrepaidInsuranceFinancedWithPromissoryNote
417841
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10705017
us-gaap Net Income Loss
NetIncomeLoss
-5839765
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-99974270
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
129323
CY2023Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
356274
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
244498
CY2023Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
71081
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
100453
CY2023Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
154119
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
91772
CY2023Q2 us-gaap Inventory Net
InventoryNet
581474
CY2022Q4 us-gaap Inventory Net
InventoryNet
436723
CY2023Q2 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
3091
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
2103
CY2023Q2 femy Accrued Clinical Trial Cost
AccruedClinicalTrialCost
295582
CY2022Q4 femy Accrued Clinical Trial Cost
AccruedClinicalTrialCost
333440
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
85191
CY2023Q2 femy Franchise Taxes
FranchiseTaxes
0
CY2022Q4 femy Franchise Taxes
FranchiseTaxes
26886
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
90424
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
0
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
21501
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
11197
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
536830
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
456714
CY2022Q4 femy Clinical Holdback Liability
ClinicalHoldbackLiability
141864
femy Clinical Holdback Retained
ClinicalHoldbackRetained
3447
femy Clinical Holdback Paid
ClinicalHoldbackPaid
328
CY2023Q2 femy Clinical Holdback Liability
ClinicalHoldbackLiability
144983
CY2023Q2 femy Clinical Holdback Current
ClinicalHoldbackCurrent
88738
CY2023Q2 femy Clinical Holdback Noncurrent
ClinicalHoldbackNoncurrent
56245
us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
0
CY2023Q2 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
0
CY2022Q2 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
0
us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
0
femy Percentage Of Restocking Fee
PercentageOfRestockingFee
0.30
CY2023Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
3899813
CY2023Q2 femy Placement Agent Fees Expenses And Offering Expenses
PlacementAgentFeesExpensesAndOfferingExpenses
547764
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15073153
us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
65216
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
62167
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
122170
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
106526
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
956653
femy Share Based Compensation Expense To Be Recognized Upon Achieving Certain Performance Condition
ShareBasedCompensationExpenseToBeRecognizedUponAchievingCertainPerformanceCondition
463101
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
493552
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y8M12D
CY2023Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1318000
CY2023Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
3899813
CY2023Q2 femy Payments Of Equity Issuance Costs
PaymentsOfEquityIssuanceCosts
547764
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1133480
CY2023Q2 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
3352049
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-2893508
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2893508
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2634101
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-2634101
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5839765
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-5839765
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-5517131
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5517131
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13107590
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13107590
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11812988
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11812988
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12493334
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12493334
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11808601
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11808601
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.47
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.47
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.47
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.47
CY2023Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1169671
CY2022Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1050606
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1169671
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1050606
CY2023Q2 femy Incremental Common Shares Attributable To Dilutive Effect Of Pre Funded Warrants Common Warrants And Placement Agent Warrants
IncrementalCommonSharesAttributableToDilutiveEffectOfPreFundedWarrantsCommonWarrantsAndPlacementAgentWarrants
3388525
CY2022Q2 femy Incremental Common Shares Attributable To Dilutive Effect Of Pre Funded Warrants Common Warrants And Placement Agent Warrants
IncrementalCommonSharesAttributableToDilutiveEffectOfPreFundedWarrantsCommonWarrantsAndPlacementAgentWarrants
0
femy Incremental Common Shares Attributable To Dilutive Effect Of Pre Funded Warrants Common Warrants And Placement Agent Warrants
IncrementalCommonSharesAttributableToDilutiveEffectOfPreFundedWarrantsCommonWarrantsAndPlacementAgentWarrants
3388525
femy Incremental Common Shares Attributable To Dilutive Effect Of Pre Funded Warrants Common Warrants And Placement Agent Warrants
IncrementalCommonSharesAttributableToDilutiveEffectOfPreFundedWarrantsCommonWarrantsAndPlacementAgentWarrants
0
CY2023Q2 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
233460
CY2022Q2 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
233460
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
233460
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
233460
CY2023Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
4791656
CY2022Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1284066
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
4791656
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1284066

Files In Submission

Name View Source Status
0001140361-23-038918-index-headers.html Edgar Link pending
0001140361-23-038918-index.html Edgar Link pending
0001140361-23-038918.txt Edgar Link pending
0001140361-23-038918-xbrl.zip Edgar Link pending
brhc20057191_10q.htm Edgar Link pending
brhc20057191_ex31-1.htm Edgar Link pending
brhc20057191_ex31-2.htm Edgar Link pending
brhc20057191_ex32-1.htm Edgar Link pending
brhc20057191_ex32-2.htm Edgar Link pending
femy-20230630.xsd Edgar Link pending
femy-20230630_cal.xml Edgar Link unprocessable
femy-20230630_def.xml Edgar Link unprocessable
femy-20230630_lab.xml Edgar Link unprocessable
femy-20230630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
brhc20057191_10q_htm.xml Edgar Link completed
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending